Acute myeloid leukemia (AML) has been one of the most promising targets of HH inhibition therapy, either with Smo inhibitors or with further downstream inhibitors of GLI1 and GLI2 activators. The gene discussed is GLI2; the disease is acute myeloid leukemia.